BIOGBs Stock Overview

A healthcare company, provides probiotic products worldwide. More details

BIOGBs fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	6/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 37.8% below our estimate of its fair value

Earnings are forecast to grow 3.35% per year

Earnings grew by 60.5% over the past year

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

BioGaia AB (publ) Competitors

Genus

LSE:GNS

UK£998.5m

Bioventix

AIM:BVXP

UK£167.0m

Ergomed

AIM:ERGO

UK£701.1m

hVIVO

AIM:HVO

UK£134.0m

Price History & Performance

Summary of share price highs, lows and changes for BioGaia
Historical stock prices
Current Share Price	SEK 95.85
52 Week High	SEK 112.40
52 Week Low	SEK 92.08
Beta	0.63
1 Month Change	0%
3 Month Change	n/a
1 Year Change	10.24%
3 Year Change	-4.34%
5 Year Change	39.72%
Change since IPO	117.84%

Recent updates

Shareholder Returns

	BIOGBs	GB Biotechs	GB Market
7D	0%	-5.1%	-2.2%
1Y	10.2%	-24.5%	2.4%

Return vs Industry: BIOGBs exceeded the UK Biotechs industry which returned -28.7% over the past year.

Return vs Market: BIOGBs exceeded the UK Market which returned -2.4% over the past year.

Price Volatility

Is BIOGBs's price volatile compared to industry and market?
BIOGBs volatility
BIOGBs Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: BIOGBs has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BIOGBs's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	213	Theresa Agnew	www.biogaia.com

BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.

BioGaia AB (publ) Fundamentals Summary

How do BioGaia's earnings and revenue compare to its market cap?
BIOGBs fundamental statistics
Market cap	SEK 10.15b
Earnings (TTM)	SEK 437.42m
Revenue (TTM)	SEK 1.27b

23.2x

P/E Ratio

8.0x

P/S Ratio

Is BIOGBs overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOGBs income statement (TTM)
Revenue	SEK 1.27b
Cost of Revenue	SEK 340.23m
Gross Profit	SEK 932.79m
Other Expenses	SEK 495.37m
Earnings	SEK 437.42m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 07, 2024

Earnings per share (EPS)	4.33
Gross Margin	73.27%
Net Profit Margin	34.36%
Debt/Equity Ratio	0%

How did BIOGBs perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

33%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/09 02:39
End of Day Share Price	2023/09/11 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioGaia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Christopher Uhde	ABG Sundal Collier Sponsored
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Mattias Häggblom	Danske Bank